OvaSure Guidance, June 4, 2009

The Society of Gynecologic Oncologists has issued a position statement on a new ovarian cancer screening test called OvaSure™. The Foundation for Women’s Cancer is sharing this statement with you as a Guidance to Women.

We all share the goal of early detection of ovarian cancer, but the OvaSure™ test has not undergone the rigorous clinical trials testing needed to demonstrate its safety and efficacy. For a screening test such as this to be considered effective, a clinical trial must demonstrate a reduction in deaths from ovarian cancer in a population of women evaluated with the test.

You might ask what is the harm in endorsing any test that might help reduce deaths from ovarian cancer? The potential harm comes from several possible problems including: 1) false reassurance from a negative test; 2) the possibility of unnecessary surgeries; and 3) the significant stress and anxiety that may come from a false positive test.

We all look forward to the day when a proven screening test is available, unfortunately we aren’t there yet. Please distribute this attached SGO statement as you feel appropriate.

Spotlight

Join us on Sunday, Nov. 4, 2018, for the National Race to End Women’s Cancer at Freedom Plaza in Washington, DC.

Awareness

September is Gynecologic Cancer Awareness Month. #GCAM

Research

The FWC is proud to offer various Research Grants and Awards. Click here for more information.

Education

FREE Gynecologic Cancer Education Courses throughout the country. For more information, click here.